J. Carpenter

发表

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Marc E. Lenburg, Donald A. Berry, Olufunmilayo I. Olopade, 2011, Breast Cancer Research and Treatment.

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Barbara L. Smith, Robert Livingston, Richard L Schilsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Richard L Schilsky, Larry Norton, James N Ingle, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

How Do I Recommend Extended Adjuvant Hormonal Therapy?

J. Carpenter, A. Mehta, 2014, Current Treatment Options in Oncology.

Weight gain with breast cancer adjuvant treatment

J. Carpenter, J. Raczynski, E. Levine, 1991, Cancer.

Does radical mastectomy still have a place in the treatment of primary operable breast cancer?

C. Balch, S. Soong, J. Carpenter, 1987, Archives of surgery.

A Randomized Prospective Trial of Radical (Halsted) Mastectomy Versus Modified Radical Mastectomy in 311 Breast Cancer Patients

C. Balch, S. Soong, J. Carpenter, 1983, Annals of surgery.

Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial.

J. Carpenter, A. Bartolucci, R. Smalley, 1992, European journal of cancer.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Nola Hylton, Carolyn Mies, Olufunmilayo I Olopade, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

R. Diasio, J. Carpenter, B. E. Harris, 1991, Cancer.

Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.

D. Ettinger, J. Bertino, R. Creech, 1986, Seminars in oncology.

Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.

S. Raab, C. Vogel, J. Carpenter, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

K. Bland, H. Krontiras, C. Falkson, 2010, Clinical breast cancer.

Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.

K. Bland, A. Cantor, A. Forero, 2011, Clinical breast cancer.

Ascending myeloencephalopathy due to intrathecal vincristine sulfate. A fatal chemotherapeutic error

J. Carpenter, J. Bracikowski, Michael E. Williams, 1983, Cancer.

Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients.

J. Carpenter, K. Vance, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic breast cancer: preliminary results with oral hormonal therapy.

J. Bertino, R. Creech, J. Carpenter, 1985, Seminars in oncology.

Splenectomy for hematologic disease.

J. Carpenter, H. L. Laws, M. Conrad, 1979, Surgery, gynecology & obstetrics.

The pathogenesis and clinical significance of cytologically detectable oral Candida in acute leukemia

J. Carpenter, B. Rodu, M. R. Jones, 1988, Cancer.

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.

R. Diasio, J. Carpenter, J T Carpenter, 1988, The Journal of clinical investigation.

Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer

J. Baselga, M. Campone, J. Boni, 2005 .

Use of megestrol acetate in advanced breast cancer on a single-daily-dose schedule.

J. Carpenter, L. Peterson, 1985, Seminars in oncology.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008

M. Fackler, S. Sukumar, E. Gabrielson, 2017, Breast Cancer Research and Treatment.

Familial pheochromocytoma, hypercalcemia, and von Hippel-Lindau disease. A ten year study of a large family.

J. Carpenter, N. Atuk, M. P. Walzak, 1979, Medicine.

Bone Marrow Necrosis

L. Cerezo, J. Carpenter, M. Kies, 1980, Cancer.

Significant Impairment in Immune Recovery After Cancer Treatment

D. Kang, J. Carpenter, Na-Jin Park, 2009, Nursing research.

Breast cancer: incidence, nutritional concerns, and treatment approaches.

J. Carpenter, H. Lane, 1987, Journal of the American Dietetic Association.

Agranulocytosis associated with disopyramide therapy.

J. Carpenter, M. Conrad, D. Thrasher, 1978, JAMA.

The use of anthracyclines in the adjuvant treatment of breast cancer.

J. Carpenter, E. Lowenthal, 1995, Cancer treatment reviews.

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

Jack Cuzick, R. Collins, J. Crowley, 1988 .

Phase II evaluation of bolus gallium nitrate in lymphoproliferative disorders: a Southeastern Cancer Study Group trial.

J. Carpenter, A. Bartolucci, J. Keller, 1986, Cancer treatment reports.

Improved Outcomes From Adding Sequent ia l Pacl i taxe l but Not From Escalat ing Doxorubic in Dose in an Adjuvant Chemotherapy Regimen for Pat ients With Node-Pos i t i ve Pr imary Breast Cancer

D. Berry, R. Schilsky, S. Martino, 2003 .

Mithramycin in the treatment of systemic mastocytosis.

J. Carpenter, T. Murad, M. Conrad, 1975, Annals of internal medicine.

A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer.

C. Jones, K. Bland, A. Forero, 2009 .

Favorable factors in the adjuvant therapy of breast cancer

D. Richards, J. Carpenter, H. L. Laws, 1982, Cancer.

Progestational agents in the treatment of breast cancer.

J. Carpenter, 1988, Cancer treatment and research.

Pheochromocytoma in von Hippel-Lindau disease: clinical presentation and mutation analysis in a large, multigenerational kindred.

M. Vance, J. Carpenter, C. Stolle, 1998, The Journal of clinical endocrinology and metabolism.

Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial.

C. Vogel, J. Carpenter, R. Weiner, 1986, Cancer treatment reports.

Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.

R. Diasio, R. Zhang, J. Carpenter, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer

J. Lefante, C. Vogel, J. Carpenter, 1983, Breast Cancer Research and Treatment.

Bone marrow necrosis and degeneration.

J. Carpenter, M. Conrad, M. Norgard, 1979, Archives of internal medicine.

Kunisada's World

J. Carpenter, J. Rimer, Sebastian Izzard, 1993 .

Dose effects of relaxation practice on immune responses in women newly diagnosed with breast cancer: an exploratory study.

D. Kang, J. Carpenter, Na-Jin Park, 2011, Oncology nursing forum.

Estradiol in Breast Cancer Treatment

P. Munster, J. Carpenter, 2016 .

Estradiol in breast cancer treatment: reviving the past.

P. Munster, J. Carpenter, 2009, JAMA.

TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer

R. Wahl, L. Carey, J. Leal, 2015, The Journal of Nuclear Medicine.

Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer.

K. Bland, A. Forero, H. Krontiras, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early change in 18-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) to predict response to preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer: Translational breast cancer research consortium (TBCRC008).

R. Wahl, J. Leal, N. Khouri, 2012 .

Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.

C. Presant, J. Carpenter, A. Bartolucci, 1986, Cancer treatment reports.

Comparison of adjuvant chemotherapy versus loco-regional radiotherapy followed by adjuvant chemotherapy in breast cancer patients with 4 or more positive axillary nodes: A southeastern cancer study group study

J. Carpenter, A. Bartolucci, V. Marcial, 1989 .

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases

C. Perou, E. Winer, J. Parker, 2014, Breast Cancer Research and Treatment.

Paradigm Shift in Adjuvant Treatment of Receptor Positive Premenopausal Breast Cancer Patients ? Not Yet !

Barbara L. Smith, D. Berry, E. Winer, 2003 .

Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial.

C. Vogel, J. Carpenter, G. Wang, 1986, Cancer treatment reports.

Southeastern Cancer Study Group: breast cancer studies 1972-1982.

J. Lefante, C. Perez, C. Vogel, 1983, International journal of radiation oncology, biology, physics.

Autoimmune hemolytic anemia associated with a hypernephroma.

J. Carpenter, R. Gualtieri, D. Mohler, 1985, Southern medical journal.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

A consultant-extender system for breast cancer adjuvant chemotherapy.

E Mesel, J. Carpenter, D. Wirtschafter, 1979, Annals of internal medicine.

Less Toxic Chemotherapy in Locally Advanced Breast Cancer

K. Bland, S. Bae, A. Forero, 2020, Southern medical journal.

Bone marrow necrosis

J. Carpenter, M. Conrad, 1979, American journal of hematology.

Facilitating the Medical Innovation Adoption Process with Clinical Algorithms

John Carpenter, David D. Wirtschafter, Richard Gams, 1978, Jerusalem Conference on Information Technology.